Most cited papers from Galapagos (Netherlands)

Galapagos (Netherlands)

What are the most cited papers from Galapagos (Netherlands)?

The most cited paper from Galapagos (Netherlands) is "Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours" (Angeliki Malliri, Rob A. van der Kammen, Kristopher P. Clark et al., 2002), with 386 citations. Next come "Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial" (258) and "Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial" (207).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 14 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours Angeliki Malliri, Rob A. van der Kammen, Kristopher P. Clark et al. · Nature	Jun 2002	386
2	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial Désirée M F M van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet Open access	22 Oct 2018	258
3	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial Philip J. Mease, Laura C. Coates, Philip Helliwell et al. · The Lancet Open access	22 Oct 2018	207
4	The Orphan G Protein–Coupled Receptor 3 Modulates Amyloid-Beta Peptide Generation in Neurons Amantha Thathiah, Kurt Spittaels, Marcel Hoffmann et al. · Science	12 Feb 2009	201
5	Development of a Gut-on-a-Chip Model for High Throughput Disease Modeling and Drug Discovery Claudia Beaurivage, Elena Naumovska, Yee Chang et al. · International Journal of Molecular Sciences Open access	12 Nov 2019	187
6	Development of a human primary gut-on-a-chip to model inflammatory processes Claudia Beaurivage, Austė Kanapeckaitė, Cindy J.M. Loomans et al. · Scientific Reports Open access	8 Dec 2020	172
7	Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis Toby M. Maher et al. · JAMA Open access252 authors	9 May 2023	140
8	Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington’s disease Xiao‐Hong Lu et al. · Science Translational Medicine	24 Dec 2014	140
9	Histological and Functional Benefit Following Transplantation of Motor Neuron Progenitors to the Injured Rat Spinal Cord Sharyn L. Rossi, Gabriel Nistor, Tanya J. Wyatt et al. · PLoS ONE Open access	29 Jul 2010	130
10	A direct androgenic involvement in the expression of human corticotropin-releasing hormone A-M Bao, David F. Fischer, Yi‐Hui Wu et al. · Molecular Psychiatry	31 Jan 2006	115
11	Adenoviral Vectors Expressing siRNAs for Discovery and Validation of Gene Function Gert‐Jan Arts, Ellen Langemeijer, Rudi Tissingh et al. · Genome Research Open access	2003	93
12	A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease Daniel G. Todd, Ian Gowers, Simon DOWLER et al. · PLoS ONE Open access	4 Feb 2014	91
13	Structure-Guided Design of Selective Epac1 and Epac2 Agonists Frank Schwede, Daniela Bertinetti, Carianne N. Langerijs et al. · PLoS Biology Open access	20 Jan 2015	88
14	The α7 nicotinic acetylcholine receptor on fibroblast‐like synoviocytes and in synovial tissue from rheumatoid arthritis patients: A possible role for a key neurotransmitter in synovial inflammation Marjolein A. van Maanen, Susanne P. Stoof, Esmerij P. van der Zanden et al. · Arthritis & Rheumatism	29 Apr 2009	85
15	Arrayed adenoviral expression libraries for functional screening Frits Michiels et al. · Nature Biotechnology	30 Sep 2002	84
16	Recombinant adenovirus vectors with knobless fibers for targeted gene transfer Victor W. van Beusechem, Angelique L. C. T. van Rijswijk, Helmuth H. G. van Es et al. · Gene Therapy	Nov 2000	82
17	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years Kevin L. Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi et al. · Annals of the Rheumatic Diseases Open access	5 Nov 2021	81
18	Basal Cells Contribute to Innate Immunity of the Airway Epithelium through Production of the Antimicrobial Protein RNase 7 Gimano D. Amatngalim, Yolanda van Wijck, Yvonne de Mooij-Eijk et al. · The Journal of Immunology	26 Feb 2015	80
19	Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins Douglas Macdonald, Michela Tessari, Ivette Boogaard et al. · PLoS ONE Open access	9 May 2014	78
20	The rationale for targeting TGF ‐β in chronic liver diseases Gianluigi Giannelli, Wolfgang Mikulits, Steven Dooley et al. · European Journal of Clinical Investigation Open access	29 Jan 2016	74
21	Rapid determination of adenoviral vector titers by quantitative real-time PCR Libin Ma, Hans A.R. Bluyssen, Marc De Raeymaeker et al. · Journal of Virological Methods	Apr 2001	69
22	Cellular Players in Lung Fibrosis Annemarie Lekkerkerker, Jamil Aarbiou, Thomas van Es et al. · Current Pharmaceutical Design	15 Aug 2012	68
23	Antibacterial Defense of Human Airway Epithelial Cells from Chronic Obstructive Pulmonary Disease Patients Induced by Acute Exposure to Nontypeable Haemophilus influenzae: Modulation by Cigarette Smoke Gimano D. Amatngalim, Jasmijn A. Schrumpf, Almira Henic et al. · Journal of Innate Immunity Open access	2017	59
24	CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials Scott Cameron Bell, Peter J. Barry, K. De Boeck et al. · Journal of Cystic Fibrosis Open access	3 May 2019	56
25	The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1 Elly M. Hol, Fred W. van Leeuwen, David F. Fischer · Trends in Molecular Medicine Review	18 Oct 2005	52
26	Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in human primary cells Olaf Voets, Frans J. Tielen, Edo Elstak et al. · PLoS ONE Open access	11 Aug 2017	50
27	Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish Suzanne Camus, Celia Quevedo, Sergio Ménendez et al. · Oncogene	19 Dec 2011	48
28	Expression of Rho GTPases using retroviral vectors Frits Michiels, Rob A. van der Kammen, Lennert Janssen et al. · Methods in enzymology on CD-ROM/Methods in enzymology Book chapter	2000	47
29	The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages Stephanie Ley, Andreas Weigert, Benjamin Weichand et al. · Oncogene	12 Mar 2012	46
30	Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies Walter Reinisch, Wayne J.G. Hellstrom, Radboud J. E. M. Dolhain et al. · Annals of the Rheumatic Diseases Open access	3 May 2023	45
31	Mutant ubiquitin decreases amyloid β plaque formation in a transgenic mouse model of Alzheimer’s disease Paula van Tijn, Frank J.A. Dennissen, Romina J. G. Gentier et al. · Neurochemistry International	14 Jul 2012	39
32	Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions Mathieu Uzzan, Yoram Bouhnik, María T. Abreu et al. · Journal of Crohn s and Colitis	2 Feb 2023	38
33	Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial) Walter P. Maksymowych, Mikkel Østergaard, Robert Landewé et al. · Lara D. Veeken Open access	4 Aug 2021	38
34	MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases Wayne J.G. Hellstrom, Radboud J. E. M. Dolhain, Timothy E. Ritter et al. · Advances in Therapy Open access	25 May 2022	37
35	Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review Kevin L. Winthrop, John Dudley Isaacs, Leonard H. Calabrese et al. · Seminars in Arthritis and Rheumatism Open access	29 Oct 2022	35
36	Identification and Characterization of DC-SCRIPT, a Novel Dendritic Cell-Expressed Member of the Zinc Finger Family of Transcriptional Regulators Vassilis Triantis, Dagmar Eleveld Trancikova, Maaike W.G. Looman et al. · The Journal of Immunology	2006	35
37	A 24‐Week , Phase IIa , Randomized, Double‐Blind , Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis Dinesh Khanna, Christopher P. Denton, Daniel E. Furst et al. · Arthritis & Rheumatology Open access	14 Feb 2023	33
38	Normalization of Prandial Blood Glucose and Improvement of Glucose Tolerance by Liver-Specific Inhibition of SH2 Domain–Containing Inositol Phosphatase 2 (SHIP2) in Diabetic KKAy Mice Rolf Grempler, Darya Zibrova, Corinna Schoelch et al. · Diabetes Open access	28 Aug 2007	32
39	Filgotinib in Active Noninfectious Uveitis Sunil K. Srivastava, Timothy R. Watkins, Quan Dong Nguyen et al. · JAMA Ophthalmology Open access	18 Jul 2024	31
40	Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial Silvio Danese, Marc Ferrante, Brian G. Feagan et al. · The American Journal of Gastroenterology Open access	23 Aug 2022	31
41	Ubiquitin proteasome system as a pharmacological target in neurodegeneration Elly M. Hol, David F. Fischer, Huib Ovaa et al. · Expert Review of Neurotherapeutics	Sep 2006	31
42	Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses Mohamed Zouambia, David F. Fischer, Barbara Hobo et al. · PROTEOMICS	18 Feb 2008	30
43	High-throughput 3D microvessel-on-a-chip model to study defective angiogenesis in systemic sclerosis Bart Kramer, Claudio Corallo, Angelique van den Heuvel et al. · Scientific Reports Open access	8 Oct 2022	29
44	Making (anti-) sense out of huntingtin levels in Huntington disease Melvin M. Evers, Menno H. Schut, Barry A. Pepers et al. · Molecular Neurodegeneration Open access	27 Apr 2015	29
45	Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial Walter P. Maksymowych, Mikkel Østergaard, Robert Landewé et al. · Lara D. Veeken Open access	13 Oct 2021	26
46	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR) Ana‐Maria Orbai, Alexis Ogdie, Laure Gossec et al. · Lara D. Veeken Open access	30 Aug 2019	26
47	New Semi-Automated Computer-Based System for Assessing the Purge of Mutagenic Impurities Michael J. Burns et al. · Organic Process Research & Development Open access	4 Oct 2019	25
48	Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale Peter L. Bonate, Tianli Wang, Paul C. C. M. Passier et al. · Journal of Pharmacokinetics and Pharmacodynamics Open access	14 Sep 2018	23
49	Biology calls the targets: combining RNAi and disease biology Helmuth H. G. van Es, Gert‐Jan Arts · Drug Discovery Today	Oct 2005	23
50	Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE Stefan Schreiber, Gerhard Rogler, Mamoru Watanabe et al. · Alimentary Pharmacology & Therapeutics Open access	18 Sep 2023	22

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.